Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + cyclophosphamide + dexamethasone induction followed by bortezomib + cyclophosphamide maintenance in relapsed or primary refractory multiple myeloma
NL-OMON38293Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, cyclophosphamide and dexamethasone in multiple myeloma (MM), sponsored by University Medical Center Groningen. Primary endpoints: Toxicity of induction and maintenance therapy and Efficacy of induction and maintenance therapy. Started Sep 2008; status: active, not recruiting.
02
Drugs
bortezomibcyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON38293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38293.